- Home
- JRVR vs AMRN Comparison
JRVR vs AMRN Comparison
Compare JRVR & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$14.45
Company Overview
Basic Information| Metric | JRVR | AMRN |
|---|---|---|
| Founded | 2002 | 1989 |
| Country | United States | Ireland |
| Employees | 578 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.7M | 339.8M |
| IPO Year | 2014 | 1998 |
Fundamental Metrics
Financial Performance| Metric | JRVR | AMRN |
|---|---|---|
| Price | $6.13 | $14.45 |
| Analyst Decision | Hold | Strong Sell |
| Analyst Count | 3 | 1 |
| Target Price | $7.33 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 260.9K | 61.8K |
| Earning Date | 03-02-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 125.82 | 55.00 |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $687,614,000.00 | $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.61 | $1.26 |
| P/E Ratio | $7.96 | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $3.85 | $0.39 |
| 52 Week High | $7.20 | $20.90 |
Technical Indicators
Market Signals| Indicator | JRVR | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 40.57 | 43.34 |
| Support Level | $6.07 | $13.63 |
| Resistance Level | $6.88 | $14.55 |
| Average True Range (ATR) | 0.19 | 0.72 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 30.56 | 6.51 |
Price Performance
Historical Comparison JRVR
AMRN
About JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.